TCGA-H7-8502-01A-11R-2403-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.560
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.530
- MYC_TARGETS_V1+0.510
- MITOTIC_SPINDLE+0.490
- ANDROGEN_RESPONSE+0.410
- MTORC1_SIGNALING+0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.360
- UNFOLDED_PROTEIN_RESPONSE+0.350
- CHOLESTEROL_HOMEOSTASIS+0.330
Top 10 suppressed
- KRAS_SIGNALING_DN-0.230
- ALLOGRAFT_REJECTION-0.160
- BILE_ACID_METABOLISM-0.150
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.130
- XENOBIOTIC_METABOLISM-0.120
- COAGULATION-0.060
- HEME_METABOLISM-0.060
- KRAS_SIGNALING_UP-0.020
- MYOGENESIS-0.010
- SPERMATOGENESIS-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CV-7440-01A-11R-2132-07 | — | — | 0.879 |
| 2 | SRR9879279 | — | cohortA1 | 0.878 |
| 3 | BS_F6V1Y4QS | Glial-neuronal tumor NOS | — | 0.865 |
| 4 | 1B940F72-3C90-43C4-9267-185F21D10AC9 | — | — | 0.861 |
| 5 | 50DE1FDE-B85E-4677-B0F8-08275DA41A6E | — | — | 0.861 |
| 6 | TCGA-56-7222-01A-11R-2045-07 | — | cohortSQ1 | 0.857 |
| 7 | SRR934851 | — | — | 0.850 |
| 8 | 266354 | EPN | EPN Tumor | 0.850 |
| 9 | MNG296 | — | — | 0.848 |
| 10 | SRR934935 | — | — | 0.848 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.510 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.490 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.410 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.360 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.320 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.260 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.240 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.220 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.180 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |